BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Lee Pharmaceuticals (LPHM) Announces Third Quarter Results


10/19/2005 5:11:43 PM

LOS ANGELES, Aug. 9 /PRNewswire-FirstCall/ -- Lee Pharmaceuticals (OTC Bulletin Board symbol: LPHM) reported results for the third quarter ended June 30, 2004. The Company reported a net loss of $432,000, or 11 cents per share, for the three months ended June 30, 2004, as compared to a $221,000 loss (or 5 cents per share) for the three months ended June 30, 2003. Gross revenues for the three months ended June 30, 2004, were $1,810,000, a decrease of approximately $620,000, or 26%, from the comparable three months ended June 30, 2003. The Company reported lower sales volume of various over-the- counter (OTC) products; namely, the Lee(R) Lip-Ex(R) line, the private label segment, depilatories and Lee Nails(R) category. These decreases were partially offset by increases in other over-the-counter items along with a newly acquired brand.

Net revenues decreased approximately $569,000, or 25%, for the three months ended June 30, 2004, as compared to the three months ended June 30, 2003. The change in net revenues was due to the sales volume explanations discussed above. The Company's sales returns decreased approximately $48,000, or 30%, when comparing the three months ended June 30, 2004 and 2003.

The Company realized other income of approximately $94,000 for the three months ended June 30, 2004, as compared to $74,000 for the comparable three months ended June 30, 2003. The other income, for the three months ended June 30, 2004, pertains to realized gains related to the sale of several product lines (approximately $56,000). The realized gains pertain to the recognition of the earned portion of deferred income of consulting agreements arising from the sale of these product lines. Also included in other income is approximately $39,000 arising from the service agreement with Monticello Drug Company. For the three months ended June 30, 2003, the Company realized other income related to the sale of two product lines ($37,000) along with $39,000 which was the Company's portion of the net profits from its investment with Monticello Drug Company.

The Company reported a net loss of $898,000, or 22 cents per share, for the nine months ended June 30, 2004, as compared to a $275,000 loss (or 7 cents per share) for the nine months ended June 30, 2003. Gross revenues for the nine months ended June 30, 2004, were $7,183,000, a decrease of approximately $763,000, or 10%, from the comparable nine months ended June 30, 2003. The decrease was due to lower sales volume of various over-the-counter (OTC) products; namely, the Lee(R) Lip-Ex(R) line and Lee Nails(R) category. These decreases were partially offset by increases in other over-the-counter items, the private label segment along with a newly acquired brand.

Net revenues decreased approximately $888,000, or 12%, for the nine months ended June 30, 2004, as compared to the nine months ended June 30, 2003. The change in net revenues was due to the gross revenues explanations discussed above. The Company's sales returns increased $132,000, or 19%, when comparing the nine months ended June 30, 2004 and 2003. This increase was the result of higher returned sales allowances during March 2004 due to overstocked items.

During the nine months ended June 30, 2004, the Company realized other income in the amount of $381,000 as compared to $270,000 for the nine months ended June 30, 2004 and 2003 respectively. This increase pertains to the

gains from the sale of several product lines along with the Company's profit arising from a service agreement with Monticello Drug Company.

A comparison of the operating results is as follows: Three Months Ended Nine Months Ended June 30 June 30 (000 omitted) (000 omitted) 2004 2003 2004 2003 Gross revenues $1,810 $2,430 $7,183 $7,946 Net revenues $1,680 $2,249 $6,265 $7,153 Net (loss) $(432) $(221) $(898) $(275) Per share: Net (loss) $(.11) $(.05) $(.22) $(.07)

Lee Pharmaceuticals is engaged in the purchase, manufacture, and marketing of a range of consumer products, including over-the-counter drug items, health and beauty aids, cosmetics and prescription drug products containing controlled substances, and dental/orthodontic products.

Lee Pharmaceuticals

CONTACT: Michael L. Agresti of Lee Pharmaceuticals, +1-626-442-3141,ext. 3219


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->